Press release
Schizophrenia Market Set to Grow Substantially Through 2034, DelveInsight Projects | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion Pharma
The Key Schizophrenia Companies in the market include - Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmaceuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others.DelveInsight's "Schizophrenia Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Schizophrenia, historical and forecasted epidemiology as well as the Schizophrenia market trends in the United States, EU4 (Germany, Spain, Italy, France) the United Kingdom and Japan.
To Know in detail about the Schizophrenia market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Schizophrenia Market Forecast [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Some of the key facts of the Schizophrenia Market Report:
*
The Schizophrenia market size was valued ~USD 7,972 million in 2022 and is anticipated to grow with a significant CAGR during the study period (2020-2034)
*
In March 2025, LB Pharmaceuticals Inc., a clinical-stage biopharma company focused on developing innovative treatments for neuropsychiatric disorders such as schizophrenia, has shared new positive findings from its NOVA1 Phase 2 clinical trial of LB-102 in patients experiencing acute schizophrenia exacerbations. The data was presented at the 2025 Annual Congress of the Schizophrenia International Research Society (SIRS), currently taking place in Chicago.
*
In February 2025, The September 2024 approval of xanomeline-trospium chloride (Cobenfy; Bristol Myers Squibb) marks the first novel schizophrenia treatment in 70 years. While some experts have welcomed the milestone, others remain cautious. Unlike traditional antipsychotics that target dopamine D2 receptors, this therapy works through muscarinic acetylcholine receptors, offering a distinct mechanism of action.
*
In January 2025, German pharmaceutical leader Boehringer Ingelheim revealed that its investigational drug iclepertin, intended to treat cognitive impairment in schizophrenia patients, did not meet any primary or secondary endpoints across three Phase III trials. The CONNEX program results showed no significant cognitive or functional improvements over placebo after six months. However, the company noted that iclepertin maintained a favorable safety profile.
*
In January 2025, Segal Trials, a private clinical research organization focused on acute schizophrenia and other psychiatric conditions, has shared its enrollment performance data from its involvement in NOVA-a Phase 2 dose-finding study in adults with acute schizophrenia assessing LB-102, a once-daily oral small molecule and potential first-in-class benzamide antipsychotic.
*
In December 2024, Adams Clinical, LLC ("Adams" or the "Company"), a prominent neuroscience-focused clinical trial site network, announced that it has reached an agreement to partner with InSite Clinical Research ("InSite"). InSite, based in the Dallas-Fort Worth metroplex, specializes in conducting inpatient and outpatient clinical trials for psychiatric and neurological conditions, including schizophrenia.
*
In November 2024, AbbVie announced that its two Phase 2 EMPOWER trials of emraclidine, a once-daily oral monotherapy for adults with schizophrenia experiencing acute psychotic symptoms, failed to meet the primary endpoint. The trials revealed no statistically significant improvement in the Positive and Negative Syndrome Scale (PANSS) total score when compared to placebo at week 6.
*
In September 2024, Bristol Myers Squibb (NYSE: BMY) announced that the U.S. Food and Drug Administration (FDA) has granted approval for COBENFY Trademark (xanomeline and trospium chloride), an oral treatment for adult schizophrenia. COBENFY marks the first new class of medication in decades, offering a novel approach by specifically targeting M1 and M4 receptors in the brain, without blocking D2 receptors.
*
In May 2024, Teva and Medincell reported positive results from the Phase III SOLARIS trial, which evaluated the efficacy of TEV-'749 (olanzapine), a once-monthly subcutaneous long-acting injectable for adults with schizophrenia. SOLARIS is a multinational, multicenter, randomized, double-blind, placebo-controlled study designed to assess the efficacy, safety, and tolerability of olanzapine extended-release injectable suspension for subcutaneous use in patients aged 18-65 with schizophrenia.
*
In April 2024, Bristol Myers Squibb (BMS) has released new interim data from the Phase III EMERGENT-4 open-label extension trial, showing that KarXT (xanomeline-trospium) led to a reduction in symptoms in adults with schizophrenia.
*
In March 2024, US-based biopharmaceutical company Acadia Pharmaceuticals announced that its Phase III ADVANCE-2 clinical trial evaluating pimavanserin for treating negative symptoms of schizophrenia failed to meet its primary endpoint. The 26-week, placebo-controlled trial enrolled 454 adult participants with negative symptoms of schizophrenia who had stable control of positive symptoms through ongoing antipsychotic therapy.
*
The US holds the largest market share for schizophrenia, valued at approximately USD 5,749 million, compared to the EU4 (Germany, Italy, France, and Spain), the UK, and Japan.
*
In 2022, Germany had the largest schizophrenia market size among the EU4 and the UK, at approximately USD 432 million. This market is expected to grow further, with Germany projected to maintain the largest share, followed by the UK, by 2034.
*
In 2022, Japan's schizophrenia market was valued at approximately USD 676 million, making it the second largest market. This is expected to grow further by 2034.
*
According to DelveInsight's analysis, the total diagnosed prevalent cases of schizophrenia in the 7MM were approximately 3,796,850 in 2022, and this number is expected to rise throughout the study period (2020-2034).
*
DelveInsight's analysis estimates that in 2022, the EU4 and the UK accounted for the largest share, approximately 42%, of the total diagnosed prevalent schizophrenia cases in the 7MM. These cases are expected to increase further by 2034.
*
DelveInsight analysts reported that in 2022, the gender-specific diagnosed prevalent cases of schizophrenia in the US were approximately 757,469 for males and 655,002 for females. These numbers are expected to fluctuate throughout the forecast period (2024-2034).
*
Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmaceuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others
*
Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others
*
The Schizophrenia market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Schizophrenia pipeline products will significantly revolutionize the Schizophrenia market dynamics.
Schizophrenia Overview
Schizophrenia is a chronic and severe mental disorder that affects how a person thinks, feels, and behaves. Individuals with schizophrenia may experience symptoms such as delusions (false beliefs), hallucinations (hearing or seeing things that aren't there), disorganized thinking, and impaired cognitive abilities. It can also lead to social withdrawal and difficulty functioning in daily life. The exact cause is unknown, but it is believed to involve a combination of genetic, biological, and environmental factors. Treatment typically includes antipsychotic medications and therapy to manage symptoms and improve quality of life.
Get a Free sample for the Schizophrenia Market Forecast, Size & Share Analysis Report:
https://www.delveinsight.com/report-store/schizophrenia-market [https://www.delveinsight.com/report-store/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Schizophrenia Epidemiology
The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2020 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.
Schizophrenia Epidemiology Segmentation:
The Schizophrenia market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:
*
Total Prevalence of Schizophrenia
*
Prevalent Cases of Schizophrenia by severity
*
Gender-specific Prevalence of Schizophrenia
*
Diagnosed Cases of Episodic and Chronic Schizophrenia
Download the report to understand which factors are driving Schizophrenia epidemiology trends @ Schizophrenia Epidemiology Forecast [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Schizophrenia Drugs Uptake and Pipeline Development Activities
The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Schizophrenia market or expected to get launched during the study period. The analysis covers Schizophrenia market uptake by drugs, patient uptake by therapies, and sales of each drug.
Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.
The report also covers the Schizophrenia Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.
Schizophrenia Therapies and Key Companies
*
RP5063 (brilaroxazine): Reviva Pharmaceuticals
*
MIN-101 (roluperidone): Minerva Neurosciences
*
KarXT (xanomeline-trospium): Karuna Therapeutics
*
NUPLAZID (pimavanserin): Acadia Pharmaceuticals
*
ICELPERTIN (BI-425809): Boehringer Ingelheim
*
SEP-363856 (ulotaront): Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical
*
OKEDI (risperidone ISM): Laboratorios Farmaceuticos Rovi
*
LYN-005: Lyndra Therapeutics
*
NW-3509/NW-3509A (evenamide): Newron Pharmaceuticals
*
CVL-231 (emraclidine): Cerevel Therapeutics
*
Seroquel Sustained Release: AstraZeneca
*
Intramuscular Olanzapine Depot: Eli Lilly and Company
*
Xanomeline and Trospium Chloride Capsules: Karuna Therapeutics
*
NBI-1117568: Neurocrine Biosciences
Discover more about therapies set to grab major Schizophrenia market share @ Schizophrenia Treatment Landscape [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Schizophrenia Market Drivers
*
Increasing popularity among individuals for long-acting injectable (LAI) antipsychotics are key factors driving growth of the global schizophrenia drugs market.
Schizophrenia Market Barriers
*
WHO's Comprehensive Mental Health Action Plan 2013- 2030 will further enhance the awareness about mental health by ensuring 100 million more people have access to quality and affordable care for mental health conditions.
Scope of the Schizophrenia Market Report
*
Study Period: 2020-2034
*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]
*
Key Schizophrenia Companies: Reviva Pharmaceuticals, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharmaceuticals, Boehringer Ingelheim, Sunovion Pharmaceuticals (Sumitomo Pharma)/Otsuka Pharmaceutical, Lyndra Therapeutics, Laboratorios Farmaceuticos Rovi, Newron Pharmaceuticals, Cerevel Therapeutics, AstraZeneca, Eli Lilly and Company, Karuna Therapeutics, Neurocrine Biosciences, and others
*
Key Schizophrenia Therapies: RP5063 (brilaroxazine), MIN-101 (roluperidone), KarXT (xanomeline-trospium), NUPLAZID (pimavanserin), ICELPERTIN (BI-425809), SEP-363856 (ulotaront), OKEDI (risperidone ISM), LYN-005, NW-3509/NW-3509A (evenamide), CVL-231 (emraclidine), Seroquel Sustained Release, Intramuscular Olanzapine Depot, Xanomeline and Trospium Chloride Capsules, NBI-1117568, and others
*
Schizophrenia Therapeutic Assessment: Schizophrenia current marketed and Schizophrenia emerging therapies
*
Schizophrenia Market Dynamics: Schizophrenia market drivers and Schizophrenia market barriers
*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies
*
Schizophrenia Unmet Needs, KOL's views, Analyst's views, Schizophrenia Market Access and Reimbursement
To know more about Schizophrenia companies working in the treatment market, visit @ Schizophrenia Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/schizophrenia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]
Table of Contents
1. Schizophrenia Market Report Introduction
2. Executive Summary for Schizophrenia
3. SWOT analysis of Schizophrenia
4. Schizophrenia Patient Share (%) Overview at a Glance
5. Schizophrenia Market Overview at a Glance
6. Schizophrenia Disease Background and Overview
7. Schizophrenia Epidemiology and Patient Population
8. Country-Specific Patient Population of Schizophrenia
9. Schizophrenia Current Treatment and Medical Practices
10. Schizophrenia Unmet Needs
11. Schizophrenia Emerging Therapies
12. Schizophrenia Market Outlook
13. Country-Wise Schizophrenia Market Analysis (2020-2034)
14. Schizophrenia Market Access and Reimbursement of Therapies
15. Schizophrenia Market Drivers
16. Schizophrenia Market Barriers
17. Schizophrenia Appendix
18. Schizophrenia Report Methodology
19. DelveInsight Capabilities
20. Disclaimer
21. About DelveInsight
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.
Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=schizophrenia-market-set-to-grow-substantially-through-2034-delveinsight-projects-reviva-pharma-minerva-neurosciences-karuna-therapeutics-acadia-pharma-boehringer-ingelheim-sunovion-pharma]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Schizophrenia Market Set to Grow Substantially Through 2034, DelveInsight Projects | Reviva Pharma, Minerva Neurosciences, Karuna Therapeutics, Acadia Pharma, Boehringer Ingelheim, Sunovion Pharma here
News-ID: 4062076 • Views: …
More Releases from ABNewswire

Asia Forex Mentor Announces 2025 Broker Awards Recognizing Trader-Preferred Firm …
Unlike typical industry rankings driven by ad spend or insider votes, the Asia Forex Mentor Broker Awards are shaped by the trading community itself - with nominations and votes coming directly from active traders, and final decisions reviewed by a panel of respected finance experts.
SINGAPORE - October 06, 2025 - Asia Forex Mentor (AFM), a global leader in trader education and financial insights, has officially opened nominations for the 2025…

Power Up EVs On-the-Go: The Future of Charging is Here with EV Mobile Charge OC
Need a charge? Call EV Mobile Charge OC at 888-675-9555 for immediate assistance.
Image: https://www.abnewswire.com/upload/2025/10/36a7feb9bde957dd72d6c31b5879bec7.jpg
Electric vehicles (EVs) are rapidly becoming the cornerstone of modern transportation, offering a cleaner, more sustainable way to travel. However, one persistent concern for EV owners has been range anxiety - the fear of running out of power far from a charging station. This is where EV Mobile Charge OC steps in, revolutionizing how Orange County drivers…

Carvina Capital on OpenAI's $500B Private Valuation
Artificial intelligence surge, record private valuation from a secondary share sale, institutional capital rotation into model infrastructure and applied software, semiconductor and cloud supply chains in focus, agentic systems adoption accelerating, earnings sensitivity to usage growth under scrutiny
Image: https://www.abnewswire.com/upload/2025/10/88b3bdfb1889adf5f415d54c3646536e.jpg
As the trading week concludes, Carvina Capital Pte. Ltd. assesses OpenAI at a headline private valuation of $500 billion following an employee secondary that concentrates substantial institutional demand, a development that reframes…

Launch of Skinetium: Skincare That's Proudly Indian, Scientifically Honest
Glow isn't imported; it's made right here in India.
Image: https://www.abnewswire.com/upload/2025/10/6aed487fb31fd1154a1453794fbe1e42.jpg
Born on 7th August, 2025, Skinetium stands as a symbol of new-age Indian confidence, where science meets self-reliance. Inspired by the Swadeshi Movement of 1905, Skinetium redefines beauty by replacing imitation with innovation, and foreign dependence with Indian brilliance. Just as freedom fighters ignited a revolution of self-sufficiency, Skinetium is sparking a new movement: skincare that's clean, transparent, and unapologetically Made…
More Releases for Schizophrenia
Rising Mental Illness Burden Fuels Growth In The Schizophrenia Market: Pivotal F …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts
Schizophrenia Market Size Growth Forecast: What to Expect by 2025?
In the past few years, the schizophrenia market size has seen robust growth. The projected growth from $5.82 billion in 2024 to $6.11 billion in 2025, signifies a compound annual growth rate (CAGR) of 5.0%. Factors such as increased…
Clozapine Market: Transforming the Treatment Landscape for Schizophrenia
Clozapine, an atypical antipsychotic medication, has emerged as a critical treatment option for patients with treatment-resistant schizophrenia and other severe psychiatric disorders. As one of the most effective therapies available for reducing symptoms in individuals who do not respond adequately to other antipsychotic medications, clozapine plays a vital role in modern psychiatry. This article provides a comprehensive overview of the clozapine market, exploring market information, key trends, challenges, and detailed…
Schizophrenia Drugs Market Opportunity | Size | Research Report
𝐔𝐒𝐀, 𝐍𝐞𝐰 𝐉𝐞𝐫𝐬𝐞𝐲: Schizophrenia Drugs Market was valued at USD 5.3 Billion in 2018 and is projected to reach USD 8.42 Billion by 2026, growing at a CAGR of 3.66% from 2019 to 2026.
Market Overview for Schizophrenia Drugs Market
Schizophrenia Drugs Market OverviewThe schizophrenia drugs market is experiencing significant growth driven by advancements in pharmacotherapy and increasing awareness about mental health disorders. Schizophrenia, a chronic and severe mental disorder affecting millions…
Schizophrenia Drugs Market - Restoring Balance, Inspiring Hope: Schizophrenia Dr …
Newark, New Castle, USA: The "Schizophrenia Drugs Market" provides a value chain analysis of revenue for the anticipated period from 2022 to 2030. The report will include a full and comprehensive analysis of the business operations of all market leaders in this industry, as well as their in-depth market research, historical market development, and information about their market competitors
Schizophrenia Drugs Market: https://www.growthplusreports.com/report/schizophrenia-drugs-market/7871
This latest report researches the industry structure, sales, revenue,…
Schizophrenia Drugs Market - Leading the Way in Schizophrenia Treatment: Nurturi …
Newark, New Castle, USA - new report, titled Schizophrenia Drugs Market The report has been put together using primary and secondary research methodologies, which offer an accurate and precise understanding of the Schizophrenia Drugs market. Analysts have used a top-down and bottom-up approach to evaluate the segments and provide a fair assessment of their impact on the global Schizophrenia Drugs market. The report offers an overview of the market, which…
Schizophrenia Drug Market & Pipeline Insight
Schizophrenia is defined as a disorder of the brain which impacts the way in which a person acts, thinks, and sees the world. It has been observed that the patients suffering from schizophrenia generally tend to have an altered perception of reality, which reveals a significant diversion from the reality. In most cases, schizophrenia is diagnosed among people in the late teens or early adulthood. However, middle-aged people also could…